Biotech Growth (UK) Performance
| BIOG Stock | 1,150 5.00 0.43% |
On a scale of 0 to 100, Biotech Growth holds a performance score of 22. The firm shows a Beta (market volatility) of 0.66, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Biotech Growth's returns are expected to increase less than the market. However, during the bear market, the loss of holding Biotech Growth is expected to be smaller as well. Please check Biotech Growth's mean deviation, downside deviation, standard deviation, as well as the relationship between the semi deviation and coefficient of variation , to make a quick decision on whether Biotech Growth's price patterns will revert.
Risk-Adjusted Performance
Solid
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in The Biotech Growth are ranked lower than 22 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively uncertain basic indicators, Biotech Growth unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Ex Dividend Date 2001-07-04 |
1 | Why This Biotech Company Could Be a Growth Stock Powerhouse - Nasdaq | 09/04/2025 |
2 | Why This Biotech Company Could Be a Growth Stock Powerhouse - The Globe and Mail | 09/17/2025 |
3 | Protagonist Therapeutics, Inc. Stock Report Exploring a 4.82 Billion Biotechs Growth Trajectory and Analyst Confidence - DirectorsTalk Interviews | 10/21/2025 |
4 | The Biotech Growth Trust PLC - Transaction in Own Shares - Yahoo Finance UK | 11/07/2025 |
| Begin Period Cash Flow | 2.1 M | |
| Total Cashflows From Investing Activities | 115.8 M |
Biotech |
Biotech Growth Relative Risk vs. Return Landscape
If you would invest 87,000 in The Biotech Growth on August 18, 2025 and sell it today you would earn a total of 28,000 from holding The Biotech Growth or generate 32.18% return on investment over 90 days. The Biotech Growth is generating 0.4426% of daily returns and assumes 1.5905% volatility on return distribution over the 90 days horizon. Simply put, 14% of stocks are less volatile than Biotech, and 92% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Biotech Growth Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Biotech Growth's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as The Biotech Growth, and traders can use it to determine the average amount a Biotech Growth's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.2783
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | BIOG | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 1.59 actual daily | 14 86% of assets are more volatile |
Expected Return
| 0.44 actual daily | 8 92% of assets have higher returns |
Risk-Adjusted Return
| 0.28 actual daily | 22 78% of assets perform better |
Based on monthly moving average Biotech Growth is performing at about 22% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Biotech Growth by adding it to a well-diversified portfolio.
Biotech Growth Fundamentals Growth
Biotech Stock prices reflect investors' perceptions of the future prospects and financial health of Biotech Growth, and Biotech Growth fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Biotech Stock performance.
| Return On Equity | -0.28 | ||||
| Return On Asset | -0.16 | ||||
| Operating Margin | 1.02 % | ||||
| Current Valuation | 293.18 M | ||||
| Shares Outstanding | 21.96 M | ||||
| Price To Book | 1.14 X | ||||
| Price To Sales | 4.90 X | ||||
| Revenue | (77.48 M) | ||||
| Gross Profit | (75.98 M) | ||||
| EBITDA | (82.52 M) | ||||
| Net Income | (82.52 M) | ||||
| Total Debt | 5.42 M | ||||
| Book Value Per Share | 8.16 X | ||||
| Cash Flow From Operations | (5.09 M) | ||||
| Earnings Per Share | (2.62) X | ||||
| Total Asset | 226.63 M | ||||
| Retained Earnings | (965 K) | ||||
About Biotech Growth Performance
Assessing Biotech Growth's fundamental ratios provides investors with valuable insights into Biotech Growth's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Biotech Growth is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Biotech Growth is entity of United Kingdom. It is traded as Stock on LSE exchange.Things to note about Biotech Growth performance evaluation
Checking the ongoing alerts about Biotech Growth for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Biotech Growth help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Net Loss for the year was (82.52 M) with loss before overhead, payroll, taxes, and interest of (75.98 M). | |
| Biotech Growth generates negative cash flow from operations | |
| Latest headline from news.google.com: The Biotech Growth Trust PLC - Transaction in Own Shares - Yahoo Finance UK |
- Analyzing Biotech Growth's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Biotech Growth's stock is overvalued or undervalued compared to its peers.
- Examining Biotech Growth's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Biotech Growth's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Biotech Growth's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Biotech Growth's stock. These opinions can provide insight into Biotech Growth's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Biotech Stock Analysis
When running Biotech Growth's price analysis, check to measure Biotech Growth's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biotech Growth is operating at the current time. Most of Biotech Growth's value examination focuses on studying past and present price action to predict the probability of Biotech Growth's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biotech Growth's price. Additionally, you may evaluate how the addition of Biotech Growth to your portfolios can decrease your overall portfolio volatility.